Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL –positive leukemias identified by a proteomics approach

Stefan Balabanov, Artur Gontarewicz, Patrick Ziegler, Ulrike Hartmann, Winfried Kammer, Mhairi Copland, Ute Brassat, Martin Priemer, Ilona Hauber, Thomas Wilhelm, Gerold Schwarz, Lothar Kanz, Carsten Bokemeyer, Joachim Hauber, Tessa L. Holyoake, Alfred Nordheim, Tim H. Brümmendorf

Blood (2006) 109 (4): 1701–1711.

https://doi.org/10.1182/blood-2005-03-037648

Published: 2006

Journal Articles

Inhibition of Hypusination of Eukaryotic Initiation Factor 5a (eIF-5A) as a Novel a Synergistic Treatment Strategy in Imatinib-Treated BCR-ABL Positive Leukemias Identified by a Global Proteomics Approach.

Stefan Balabanov, MD, PhD, Patrick Ziegler, PhD, Ulricke Hartmann, Winfried Kammer, PhD, Mhairi Copland, MD, Martin Priemer, Thomas Wilhelm, Carsten Bokemeyer, MD, Lothar Kanz, MD, Tessa Holyoake, MD, Alfred Nordheim, PhD, Tim Bruemmendorf, MD

Blood (2005) 106 (11): 1997.

https://doi.org/10.1182/blood.V106.11.1997.1997

Published: 2005

Journal Articles

Activity Profiling of Proteasome Subunits and Deubiquitinating Enzymes in Human Hematopoetic Malignancies.

Christoph Driessen, Marianne Kraus, Jeanette Gogel, Alexander Beck, Winfried Kammer, Huib Ovaa, Herman Overkleeft, Thomas Rückrich

Blood (2005) 106 (11): 617.

https://doi.org/10.1182/blood.V106.11.617.617

Published: 2005

Journal Articles

Identification of BCR-ABL Dependent Gene Regulation by Using a Phosphoproteomics Approach.

Patrick Ziegler, PhD, Stefan Balabanov, MD PhD, Ulrike Hartmann, Winfried Kammer Kammer, PhD, Alfred Nordheim, PhD, Tim H. Brummendorf, MD

Blood (2004) 104 (11): 2944.

https://doi.org/10.1182/blood.V104.11.2944.2944

Published: 2004

Journal Articles

Identification of Hypusination Inhibitors as a Novel Therapuetical Option in BCR-ABL Positive Leukemias Using a Proteomics Approach.

Stefan Balabanov, MD PhD, Ulrike Hartmann, Winfried Kammer, PhD, Patrick Ziegler, PhD, Martin Priemer, Gerold Schwarz, Lothar Kanz, MD, Alfred Nordheim, PhD, Tim H. Brummendorf, MD

Blood (2004) 104 (11): 2957.

https://doi.org/10.1182/blood.V104.11.2957.2957

Published: 2004

NARROW

Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL –positive leukemias identified by a proteomics approach

Inhibition of Hypusination of Eukaryotic Initiation Factor 5a (eIF-5A) as a Novel a Synergistic Treatment Strategy in Imatinib-Treated BCR-ABL Positive Leukemias Identified by a Global Proteomics Approach.

Activity Profiling of Proteasome Subunits and Deubiquitinating Enzymes in Human Hematopoetic Malignancies.

Identification of BCR-ABL Dependent Gene Regulation by Using a Phosphoproteomics Approach.

Identification of Hypusination Inhibitors as a Novel Therapuetical Option in BCR-ABL Positive Leukemias Using a Proteomics Approach.

Email alerts

ASH Publications

American Society of Hematology

Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL –positive leukemias identified by a proteomics approach

Inhibition of Hypusination of Eukaryotic Initiation Factor 5a (eIF-5A) as a Novel a Synergistic Treatment Strategy in Imatinib-Treated BCR-ABL Positive Leukemias Identified by a Global Proteomics Approach.

Activity Profiling of Proteasome Subunits and Deubiquitinating Enzymes in Human Hematopoetic Malignancies.

Identification of BCR-ABL Dependent Gene Regulation by Using a Phosphoproteomics Approach.

Identification of Hypusination Inhibitors as a Novel Therapuetical Option in BCR-ABL Positive Leukemias Using a Proteomics Approach.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only